Search

Your search keyword '"Gillan, Tanya L."' showing total 26 results
Start Over Author "Gillan, Tanya L." Language english
26 results on '"Gillan, Tanya L."'

1. Ultrasensitive Detection of NOTCH1 c.7544_7545delCT Mutations in Chronic Lymphocytic Leukemia by Droplet Digital PCR Reveals High Frequency of Subclonal Mutations and Predicts Clinical Outcome in Cases with Trisomy 12

Author

Hoofd, Catherine, Huang, Steven J., Gusscott, Samuel, Lam, Sonya, Wong, Rachel, Johnston, Alexa, Ben-Neriah, Susana, Steidl, Christian, Scott, David W., Bruyere, Helene, Gillan, Tanya L., Toze, Cynthia L., Gerrie, Alina S., and Weng, Andrew P.

Published
2020
Full Text
View/download PDF

6. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort

Author

Toze, Cynthia L., Dalal, Chinmay B., Nevill, Thomas J., Gillan, Tanya L., Abou Mourad, Yasser R., Barnett, Michael J., Broady, Raewyn C., Forrest, Donna L., Hogge, Donna E., Nantel, Stephen H., Power, Maryse M., Song, Kevin W., Sutherland, Heather J., Smith, Clayton A., Narayanan, Sujaatha, Young, Sean S., Connors, Joseph M., and Shepherd, John D.

Published
2012
Full Text
View/download PDF

9. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.

Author

Lee, Lauren J., Toze, Cynthia L., Huang, Steven J. T., Gillan, Tanya L., Connors, Joseph M., Sehn, Laurie H., Bruyere, Helene, Leitch, Heather, Ramadan, Khaled M., and Gerrie, Alina S.

Subjects
RITUXIMAB, CHRONIC lymphocytic leukemia treatment, IMMUNOTHERAPY, CANCER chemotherapy, POPULATION-based case control
Abstract

Chemoimmunotherapy with rituximab improves survival in clinical trials in upfront chronic lymphocytic leukemia (CLL) treatment. This study compared clinical outcomes with and without rituximab added to first-line chemotherapy in a provincial cohort of CLL patients. Between 1973 and 2014, 1345 patients received CLL treatment: 48% with rituximab, 52% chemotherapy alone. Median overall survival (OS) and treatment-free survival (TFS) were significantly longer with rituximab: OS 8.9 vs. 6.2 years, p < .0001; TFS 3.6 vs. 2.1 years, p < .0001. Addition of rituximab to chemotherapy was a strong independent predictor of mortality with a 32% mortality reduction after controlling for co-variates (age, sex, stage, and treatment with purine analogs). This large population-based study complements clinical trial and registry data demonstrating the benefit of adding rituximab to first-line CLL therapy and adds further evidence of the efficacy of rituximab-based chemoimmunotherapy in a real-world setting. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

14. Prognostic Factors and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Vs. Non-Transplant Chronic Lymphocytic Leukemia (CLL) Patients: A Comparative Analysis with the Leukemia/BMT Program of British Columbia (BC) and the BC Provincial CLL Database

Author

Swic, Sebastian J., MacPhail, Alexander G.T., Dalal, Chinmay B., Huang, Steven J.T., Gerrie, Alina S., Nevill, Thomas J., Sutherland, Heather J., Broady, Raewyn, Nantel, Stephen H., Narayanan, Sujaatha, Song, Kevin, Abou Mourad, Yasser R, Hogge, Donna E., Power, Maryse M., Barnett, Michael J., Forrest, Donna L., Young, Sean S, Gillan, Tanya L., and Toze, Cynthia L.

Published
2014
Full Text
View/download PDF

16. Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort

Author

Dalal, Chinmay B., Shanmukhaiah, Chandrakala, Nevill, Thomas J., Barnett, Michael J., Nantel, Stephen H., Hogge, Donna E., Forrest, Donna L., Sutherland, Heather J., Song, Kevin W., Broady, Raewyn, Power, Maryse M., Narayanan, Sujaatha, Mourad, Yasser R Abou, Shepherd, John D., Young, Sean S, Gillan, Tanya L., and Toze, Cynthia L.

Published
2012
Full Text
View/download PDF

19. Outcomes for Patients Aged 60 and Over Are Similar to Younger Patients Following Reduced-Intensity Allogeneic Stem Cell Transplant for CLL

Author

Toze, Cynthia L., Dalal, Chinmay B., Nevill, Thomas J., Barnett, Michael J., Nantel, Stephen H., Forrest, Donna L., Hogge, Donna E., Sutherland, Heather J., Song, Kevin W., Mourad, Yasser Abou, Broady, Raewyn, Power, Maryse M., Narayanan, Sujaatha, Gillan, Tanya L., Smith, Clayton A., and Shepherd, John D.

Published
2011
Full Text
View/download PDF

23. Limiting the Niemann-Pick Type C critical region to a 1-cM interval.

Author

Gillan, Tanya L., Byers, David., Riddell, Christie, Neumann, Paul E., and Greer, Wenda L.

Subjects
*NEURODEGENERATION
Abstract

Presents a study to refine the position of and isolate the gene responsible for Niemann-Pick Type II (NY Type II) disease, an autosomal, recessive neurodegenerative disorder usually affecting children. Information on methods and materials used; Results of the study; Details on research efforts which are directed towards isolating and characterizing the NPC/NPD genetic defect.

Published
1997

25. Cytogenetic and molecular characterization of a de-novo cryptic deletion of 7p21 associated with an apparently balanced translocation and complex craniosynostosis.

Author

Shetty S, Boycott KM, Gillan TL, Bowser K, Parboosingh JS, McInnes B, Chernos JE, and Bernier FP

Subjects
Child, Preschool, Female, Humans, In Situ Hybridization, Fluorescence, Infant, Infant, Newborn, Chromosome Deletion, Chromosomes, Human, Pair 7 genetics, Craniosynostoses genetics, Cytogenetic Analysis methods, Translocation, Genetic
Abstract

We describe a female infant with complex craniosynostosis, significant craniofacial dysmorphism and developmental delay in which a de-novo apparently balanced translocation between chromosomes 7 and 18 [46,XX,t(7;18)(p15.3;q11.2)] was identified. Additional cytogenetic and molecular investigations identified a cryptic interstitial 7.6-10.6-Mb deletion of the region between bands 7p21.2 and 7p21.3 on the derivative chromosome 18. The deletion was of paternal origin and contained the TWIST1 gene, although her features were not completely characteristic of Saethre-Chotzen syndrome. The phenotype of this patient is likely further complicated by loss of other genes within the deleted region and/or disruption of a critical gene(s) at the sites of the breakpoints on chromosomes 7 and 18. This case illustrates the need for a systematic molecular study of breakpoints and the surrounding chromosomal regions in patients with apparently balanced rearrangements and phenotypic abnormalities.

Published
2007
Full Text
View/download PDF

26. The Simpson-Golabi-Behmel gene, GPC3, is not involved in sporadic Wilms tumorigenesis.

Author

Gillan TL, Hughes R, Godbout R, and Grundy PE

Subjects
DNA Mutational Analysis, Gene Expression, Glypicans, Humans, Membrane Proteins metabolism, Mutation, Neoplasm Proteins metabolism, Wilms Tumor metabolism, Membrane Proteins genetics, Neoplasm Proteins genetics, Wilms Tumor genetics
Abstract

Many genes have been implicated in Wilms tumor; however, only one gene, WT1, has a proven role in the development of this embryonal tumor. Wilms tumor occurs in a number of congenital syndromes including the Simpson-Golabi-Behmel syndrome (SGBS) which has phenotypic overlap with another Wilms tumor-predisposing syndrome Wiedemann-Beckwith syndrome. The putative function and expression pattern of the SGBS gene, glypican 3 (GPC3), makes it an attractive candidate Wilms tumor gene. We, therefore, hypothesized that Wilms tumors from non-SGBS patients may harbor somatic mutations of GPC3. Mutation analysis of 64 Wilms tumors was performed. One case of a tumor-specific deletion of the entire GPC3 gene and several polymorphisms were identified. GPC3 expression was evaluated in 36 Wilms tumors and 29/36 expressed GPC3. Surprisingly, we did not find evidence of functional mutations of GPC3 in sporadic Wilms tumor suggesting that GPC3 is not often directly involved in Wilms tumorigenesis., (Copyright 2003 Wiley-Liss, Inc.)

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results